4.8 Article

Pretargeted delivery of PI3K/mTOR small-molecule inhibitor-loaded nanoparticles for treatment of non-Hodgkin's lymphoma

Related references

Note: Only part of the references are listed.
Article Chemistry, Multidisciplinary

Elimination Pathways of Nanoparticles

Wilson Poon et al.

ACS NANO (2019)

Article Oncology

Cancer statistics, 2019

Rebecca L. Siegel et al.

CA-A CANCER JOURNAL FOR CLINICIANS (2019)

Article Pharmacology & Pharmacy

PLGA-PEG nanoparticles for targeted delivery of the mTOR/PI3kinase inhibitor dactolisib to inflamed endothelium

Shima Gholizadeh et al.

INTERNATIONAL JOURNAL OF PHARMACEUTICS (2018)

Article Chemistry, Multidisciplinary

Bespoke Pretargeted Nanoradioimmunotherapy for the Treatment of Non-Hodgkin Lymphoma

Kin Man Au et al.

ACS NANO (2018)

Article Pharmacology & Pharmacy

Targeting the B cell receptor pathway in non-Hodgkin lymphoma

Kelly Valla et al.

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2018)

Review Pharmacology & Pharmacy

A Revisit to the Pretargeting Concept-A Target Conversion

Guozheng Liu

FRONTIERS IN PHARMACOLOGY (2018)

Review Oncology

Antibody-drug conjugates-an emerging class of cancer treatment

Nikolaos Diamantis et al.

BRITISH JOURNAL OF CANCER (2016)

Review Chemistry, Multidisciplinary

New insights into the pretargeting approach to image and treat tumours

Malay Patra et al.

CHEMICAL SOCIETY REVIEWS (2016)

Article Education, Scientific Disciplines

Diffuse large B-cell lymphoma: R-CHOP failure-what to do?

Bertrand Coiffier et al.

HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2016)

Review Hematology

Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma

James S. Blachly et al.

BRITISH JOURNAL OF HAEMATOLOGY (2014)

Review Oncology

Status of PI3K/Akt/mTOR Pathway Inhibitors in Lymphoma

Jason R. Westin

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2014)

Article Medicine, General & Internal

Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

Richard R. Furman et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

Review Oncology

B-cell receptor signaling as a driver of lymphoma development and evolution

Carsten U. Niemann et al.

SEMINARS IN CANCER BIOLOGY (2013)

Review Hematology

The B-cell receptor signaling pathway as a therapeutic target in CLL

Jennifer A. Woyach et al.

BLOOD (2012)

Review Immunology

PI3K Functions in Cancer Progression, Anticancer Immunity and Immune Evasion by Tumors

Francesco Dituri et al.

CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2011)

Article Oncology

Antibody Conjugate Therapeutics: Challenges and Potential

Beverly A. Teicher et al.

CLINICAL CANCER RESEARCH (2011)

Article Nanoscience & Nanotechnology

Bioorthogonal chemistry amplifies nanoparticle binding and enhances the sensitivity of cell detection

Jered B. Haun et al.

NATURE NANOTECHNOLOGY (2010)

Article Biochemistry & Molecular Biology

Mammalian target of rapamycin (mTOR) pathway signalling in lymphomas

Elias Drakos et al.

EXPERT REVIEWS IN MOLECULAR MEDICINE (2008)

Article Oncology

Improved tumor targeting by combined use of two antitenascin antibodies

F Petronzelli et al.

CLINICAL CANCER RESEARCH (2005)

Review Oncology

The mechanisms of action of rituximab in the elimination of tumor cells

P Johnson et al.

SEMINARS IN ONCOLOGY (2003)